HRASLS3 Antibody (C-term) Blocking peptide
€363.00
In stock
SKU
AC-BP5747a
Background:
PLA2G16 specifically catalyzes the release of fatty acids from phospholipids in adipose tissue. It also has a weak lysophospholipase activity (By similarity). Tumor suppressor that may be involved in interferon-dependent cell death.
Other Names:
HRAS-like suppressor 3, HRSL3, Adipose-specific phospholipase A2, AdPLA, Group XVI phospholipase A1/A2, H-rev 107 protein homolog, HRAS-like suppressor 1, HREV107-1, HREV107-3, Renal carcinoma antigen NY-REN-65, PLA2G16, HRASLS3, HREV107
Gene Name: PLAAT3 (HGNC:17825)
Gene ID: 11145
Primary Accession: P53816
Other Accession: NP_009000
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
PLA2G16 specifically catalyzes the release of fatty acids from phospholipids in adipose tissue. It also has a weak lysophospholipase activity (By similarity). Tumor suppressor that may be involved in interferon-dependent cell death.
Other Names:
HRAS-like suppressor 3, HRSL3, Adipose-specific phospholipase A2, AdPLA, Group XVI phospholipase A1/A2, H-rev 107 protein homolog, HRAS-like suppressor 1, HREV107-1, HREV107-3, Renal carcinoma antigen NY-REN-65, PLA2G16, HRASLS3, HREV107
Gene Name: PLAAT3 (HGNC:17825)
Gene ID: 11145
Primary Accession: P53816
Other Accession: NP_009000
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review